Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Sources of further information about Childhood Non-Hodgkin Lymphoma Treatment.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Many of the improvements in childhood cancer survival have been made using combinations of known and/or new agents that have attempted to improve the best available,accepted therapy. Clinical trials in pediatrics are designed to compare potentially better therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of 2 treatment arms or by ...
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Adult NHL
Treatment of non-Hodgkin lymphoma (NHL) depends on the histologic type and stage. Many of the improvements in survival have been made using clinical trials (experimental therapy) that have attempted to improve on the best available accepted therapy (conventional or standard therapy). In asymptomatic patients with indolent forms of advanced NHL, treatment may be deferred until the patient becomes symptomatic as the disease progresses. When treatment is deferred, the clinical course of patients with indolent NHL varies; frequent and careful observation is required so that effective treatment can be initiated when the clinical course of the disease accelerates. Some patients have a prolonged indolent course, but others have disease that rapidly evolves into more aggressive types of NHL that require immediate treatment.Radiation techniques differ somewhat from those used in the treatment of Hodgkin lymphoma. The dose of radiation therapy usually varies from 25 Gy to 50 Gy and is
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL
Although localized presentations are uncommon in non-Hodgkin lymphoma (NHL), the goal of treatment should be to cure the disease in patients who are shown to have truly localized occurrence after undergoing appropriate staging procedures.Standard Treatment Options for Indolent, Stage I and Contiguous Stage II Adult NHLStandard treatment options for indolent, stage I and contiguous stage II adult NHL include the following:Radiation therapy.Rituximab with or without chemotherapy.Watchful waiting.Other therapies as designated for patients with advanced-stage disease.Radiation therapy Long-term disease control within radiation fields can be achieved in a significant number of patients with indolent stage I or stage II NHL by using dosages of radiation that usually range from 25 Gy to 40 Gy to involved sites or to extended fields that cover adjacent nodal sites.[1,2,3,4] Almost half of all patients treated with radiation therapy alone will relapse out-of-field within 10 years.Rituximab
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Adult Non-Hodgkin Lymphoma (NHL)
The NHLs are a heterogeneous group of lymphoproliferative malignancies with differing patterns of behavior and responses to treatment.Like Hodgkin lymphoma, NHL usually originates in lymphoid tissues and can spread to other organs. NHL, however, is much less predictable than Hodgkin lymphoma and has a far greater predilection to disseminate to extranodal sites. The prognosis depends on the histologic type, stage, and treatment.Incidence and MortalityEstimated new cases and deaths from NHL in the United States in 2013:New cases: 69,740.Deaths: 19,020.AnatomyNHL usually originates in lymphoid tissues.Anatomy of the lymph system.Prognosis and SurvivalThe NHLs can be divided into two prognostic groups: the indolent lymphomas and the aggressive lymphomas. Indolent NHL types have a relatively good prognosis with a median survival as long as 10 to 20 years, but they usually are not curable in advanced clinical stages. Early-stage (stage I and stage II) indolent NHL can be effectively
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Childhood NHL
Cellular Classification and Clinical PresentationIn children, non-Hodgkin lymphoma (NHL) is distinct from the more common forms of lymphoma observed in adults. While lymphomas in adults are more commonly low or intermediate grade, almost all NHL that occurs in children is high grade.[1,2,3] The World Health Organization (WHO) has classified NHL on the basis of the following: (1) phenotype (i.e., B-lineage and T-lineage or natural killer [NK] cell lineage) and (2) differentiation (i.e., precursor vs. mature).On the basis of clinical response to treatment, NHL of childhood and adolescence currently falls into the following three therapeutically relevant categories: Mature B-cell NHL (Burkitt and Burkitt-like lymphoma/leukemia and diffuse large B-cell lymphoma).Lymphoblastic lymphoma (primarily precursor T-cell lymphoma and, less frequently, precursor B-cell lymphoma).Anaplastic large cell lymphoma (mature T-cell or null-cell lymphomas).NHL associated with
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - About PDQ
PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE. PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health,the federal government's focal point for biomedical research. .
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Aggressive NHL
Aggressive non-Hodgkin lymphoma (NHL) includes the following subtypes:Diffuse large B-cell lymphoma.Mediastinal large B-cell lymphoma (primary mediastinal large B-cell lymphoma).Follicular large cell lymphoma.Anaplastic large cell lymphoma.Extranodal NK-/T-cell lymphoma.Lymphomatoid granulomatosis.Angioimmunoblastic T-cell lymphoma.Peripheral T-cell lymphoma.Enteropathy-type intestinal T-cell lymphoma.Intravascular large B-cell lymphoma (intravascular lymphomatosis).Burkitt lymphoma/diffuse small noncleaved-cell lymphoma.Lymphoblastic lymphoma.Adult T-cell leukemia/lymphoma.Mantle cell lymphoma.Polymorphic posttransplantation lymphoproliferative disorder.True histiocytic lymphoma.Primary effusion lymphoma.Diffuse Large B-cell LymphomaDiffuse large B-cell lymphoma (DLBCL) is the most common of the NHLs and comprises 30% of newly diagnosed cases. Most patients present with rapidly enlarging masses, often with both local and systemic symptoms
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Childhood Non-Hodgkin Lymphoma
Localized non-Hodgkin lymphoma in children and adolescents
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Adult NHL
A pathologist should be consulted prior to a biopsy because some studies require special preparation of tissue (e.g., frozen tissue). Knowledge of cell surface markers and immunoglobulin and T-cell receptor gene rearrangements may help with diagnostic and therapeutic decisions. The clonal excess of light-chain immunoglobulin may differentiate malignant from reactive cells. Since the prognosis and the approach to treatment are influenced by histopathology, outside biopsy specimens should be carefully reviewed by a hematopathologist who is experienced in diagnosing lymphomas. Although lymph node biopsies are recommended whenever possible, sometimes immunophenotypic data are sufficient to allow diagnosis of lymphoma when fine-needle aspiration cytology is preferred.[1,2]Historical Classification SystemsHistorically, uniform treatment of patients with non-Hodgkin lymphoma (NHL) has been hampered by the lack of a uniform classification system. In 1982, results of a consensus